Antipsychotic Exposure in Clinical High Risk of Psychosis

• DOI: 10.4088/jcp.21m14092
• Publication Date: 2022-03-18T13:47:24Z
• Authors: JiaHui Zeng; Andrea Raballo; RanPiao Gan; GuiSen Wu; YanYan Wei; LiHua Xu; XiaoChen Tang; YeGang Hu; YingYing Tang; Tao Chen; ChunBo Li; JiJun Wang; TianHong Zhang
• Keywords: Amisulpride; Aripiprazole; Typical antipsychotic

Objective: Current treatment guidelines for individuals at clinical high risk (CHR) psychosis do not recommend the prescription of antipsychotics (not even second-generation ones) as first option preventing psychosis. Yet, recent meta-analytic evidence indicates that antipsychotic exposure in CHR is relatively widespread and associated with a higher imminent transition to Therefore, we undertook this study better delineate which characteristics may lead choice whether it identifies subgroup conversion psychosis.Methods: Consecutively referred (N = 717) were assessed demographic followed up 3 years (200 did reach end follow-up time) from 2016 2021. The sample was then dichotomized, on basis prescription, prescribed (CHRAP+, n 492) or not-prescribed (CHRAP-, 225) groups, subsequently compared sociodemographic characteristics. risks CHRAP+ versus CHRAP- groups tested via survival analysis.Results: Of 717 individuals, 492 (68.62%) antipsychotics; among these antipsychotics, highest proportion used aripiprazole (n 152), by olanzapine 106), amisulpride 76), risperidone 64). group had younger age (t 2.138, P .033), female (χ2 5.084, .024), psychotic symptoms greater severity 7.910, < .001), more impaired general function 5.846, .001) than group. (27.0% vs 10.9% group, .001). Factors related positive most likely influence doctors' decision-making regarding prescripton without age, sex, education levels.Conclusions: Clinicians prescribe mainly based disorganization individuals. In pragmatic terms, finding baseline cohorts warning flag incipient designates hyper-CHR antipsychotic-naive CHR.Trial Registration: ClinicalTrials.gov identifier: NCT04010864.